Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use*; D044383:Black People / Q000706:statistics & numerical data*; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000652:urine*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011237:Predictive Value of Tests; D012008:Recurrence; D012307:Risk Factors; D013929:Thromboxane B2 / Q000031:analogs & derivatives* / Q000652:urine*; D013988:Ticlopidine / Q000627:therapeutic use; D001741:Black or African American
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010975:Platelet Aggregation Inhibitors; D013929:Thromboxane B2; C049235:11-dehydro-thromboxane B2; D013988:Ticlopidine; D001241:Aspirin